Autolus Therapeutics PE Ratio 2018-2021 | AUTL

Current and historical p/e ratio for Autolus Therapeutics (AUTL) from 2018 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Autolus Therapeutics PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Autolus Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 5.58 0.00
2021-06-30 6.64 $-2.54 0.00
2021-03-31 5.73 $-2.69 0.00
2020-12-31 8.94 $-2.76 0.00
2020-09-30 11.64 $-2.87 0.00
2020-06-30 16.03 $-2.76 0.00
2020-03-31 5.99 $-2.79 0.00
2019-12-31 13.20 $-2.88 0.00
2019-09-30 12.42 $-2.47 0.00
2019-06-30 16.10 $-1.86 0.00
2019-03-31 31.47 $-1.21 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.406B $0.002B
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76